Company profile
UK company NI668614, incorporated on 24 March 2020.
Vascular Experts | Reprogo
Here in ReproGO, we are world leaders in vascular stem cell biology. Your one stop solution for matched patient-specific cells.
Company number NI668614
Updated 07 Jul 2026 09:49
Financial period: 1 Apr 2024 to 31 Mar 2025
Reference milestones and recent Companies House filing stream events.
Company registered at Companies House
ReproGo develops technology that produces stem-cells for specific patients.
The company is a start-up focusing on developing and marketing of inducible pluripotent stem cells. In the first instance these will be for sale to R&D clients, e.g. in drug screening assays. In the future there is the potential to develop for therapeutic use
The company attracted a total of £50K of support for customer discovery ant team formation from Innovate UK through ICURe, and was invited to apply for the aid for start-ups programme for ICURe companies. This was successfully awarded and company incorporated in 2020, although commencement of the award was delayed due to the coronavirus pandemic
1 Sep 2025 to 31 Aug 2026
ReproGo is developing **VasIntel**, an AI-powered platform that simulates how real human tissues respond to genes, compounds, and disease triggers --- enabling scientists and pharmaceutical companies to reduce lab burden, de-risk decisions, and accelerate discovery. Unlike traditional approaches that rely on animal testing or generic models, VasIntel is t...
1 Mar 2021 to 30 Nov 2022
Since their advent in 2006, induced pluripotent stem cells (iPSCs) have demonstrated a huge potential for disease modelling, drug discovery and regenerative medicine. Through genetic modification, adult cells already differentiated to specific tissues are reverted back, or 'reprogrammed' to an embryonic-like state, creating cells with self-renewal propert...
